Yahoo Web Search

Search results

  1. Pierre Fabre Group. 30 May 2024. [Partners In Care] When Pierre Fabre employees help others around the world 🌍. 3 countries = 3 charitable missions in partnership with local associations 🤝. Founded in 1962 by Mr. Pierre Fabre, Pierre Fabre is an international French pharmaceutical and dermo-cosmetic group owned by a public benefit ...

  2. For the 3rd year in a row, Pierre Fabre Laboratories is proud to be listed in the World’s Best Employers ranking. This ranking, compiled by the American magazine FORBES and the independent German market research firm Statista, places Pierre Fabre at Top 6 among cosmetic companies and Top 7 among pharmaceutical companies.   This year, Pierre Fabre has moved up another 7 places in the ...

  3. Créé en 1962 par Monsieur Pierre Fabre, Pierre Fabre est un groupe pharmaceutique et dermo-cosmétique français international détenu par une fondation d'utilité publique et par ses salariés.

    • Laboratoires Pierre Fabre1
    • Laboratoires Pierre Fabre2
    • Laboratoires Pierre Fabre3
    • Laboratoires Pierre Fabre4
    • Laboratoires Pierre Fabre5
  4. Laboratoires Pierre Fabre is a French multinational pharmaceutical and cosmetics company. The company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international). [2] It is headquartered in the city of Castres , Midi-Pyrénées , France.

  5. Laboratoires Pierre Fabre est un groupe pharmaceutique et dermo-cosmétique français, créé en 1962 à Castres (Tarn) par Pierre Fabre, pharmacien et botaniste castrais. Depuis juillet 2018, le groupe a pour directeur général Eric Ducournau 3, auparavant directeur général de la division dermo-cosmétique (de 2012 à 2018).

  6. Pierre Fabre Group | 372,597 followers on LinkedIn. New ways to care | Pierre Fabre Group held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of ...

  7. People also ask

  8. May 24, 2022 · Pierre Fabre and the European Organisation for Research and Treatment of Cancer (EORTC) today announced the screening of the first patient with a resected stage II BRAF-mutant melanoma for the phase III study COLUMBUS-AD (NCT05270044; EORTC-2139-MG).

  1. People also search for